• 1
    Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269: 540-543.
  • 2
    Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995; 269: 546-549.
  • 3
    Nishina PM, Lowe S, Wang J, Paigen B. Characterization of plasma lipids in genetically obese mice: the mutants obese, diabetes, fat, tubby, and lethal yellow. Metabolism 1994; 43: 549-553.
  • 4
    Lombardo YB, Hron WT, Sobocinski KA, Menahan LA. A metabolic profile of fed and fasting genetically obese mice at 4-5 months of age. Horm Metab Res 1984; 16( Suppl. 1): 37-42.
  • 5
    Haluzik M, Colombo C, Gavrilova O, Chua S, Wolf N, Chen M, et al. Genetic background (C57BL/6J versus FVB/N) strongly influences the severity of diabetes and insulin resistance in ob/ob mice. Endocrinology 2004; 145: 3258-3264.
  • 6
    Cohen P, Miyazaki M, Socci ND, Hagge-Greenberg A, Liedtke W, Soukas AA, et al. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 2002; 297: 240-243.
  • 7
    Singh A, Wirtz M, Parker N, Hogan M, Strahler J, Michailidis G, et al. Leptin-mediated changes in hepatic mitochondrial metabolism, structure, and protein levels. Proc Natl Acad Sci U S A 2009; 106: 13100-13105.
  • 8
    Asilmaz E, Cohen P, Miyazaki M, Dobrzyn P, Ueki K, Fayzikhodjaeva G, et al. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J Clin Invest 2004; 113: 414-424.
  • 9
    Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002; 109: 1345-1350.
  • 10
    Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995; 83: 1263-1271.
  • 11
    Ghilardi N, Ziegler S, Wiestner A, Stoffel R, Heim MH, Skoda RC. Defective STAT signaling by the leptin receptor in diabetic mice. Proc Natl Acad Sci U S A 1996; 93: 6231-6235.
  • 12
    Liang CP, Tall AR. Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J Biol Chem 2001; 276: 49066-49076.
  • 13
    Huynh FK, Levi J, Denroche HC, Gray SL, Voshol PJ, Neumann UH, et al. Disruption of hepatic leptin signaling protects mice from age- and diet-related glucose intolerance. Diabetes 2010; 59: 3032-3040.
  • 14
    Lee Y, Wang MY, Kakuma T, Wang ZW, Babcock E, McCorkle K, et al. Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J Biol Chem 2001; 276: 5629-5635.
  • 15
    Cohen P, Zhao C, Cai X, Montez JM, Rohani SC, Feinstein P, et al. Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest 2001; 108: 1113-1121.
  • 16
    Levi J, Huynh FK, Denroche HC, Neumann UH, Glavas MM, Covey SD, et al. Hepatic leptin signalling and subdiaphragmatic vagal efferents are not required for leptin-induced increases of plasma IGF binding protein-2 (IGFBP-2) in ob/ob mice. Diabetologia 2012; 55: 752-762.
  • 17
    Huang W, Metlakunta A, Dedousis N, Ortmeyer HK, Stefanovic-Racic M, O'Doherty RM. Leptin augments the acute suppressive effects of insulin on hepatic very low-density lipoprotein production in rats. Endocrinology 2009; 150: 2169-2174.
  • 18
    Lam NT, Covey SD, Lewis JT, Oosman S, Webber T, Hsu EC, et al. Leptin resistance following over-expression of protein tyrosine phosphatase 1B in liver. J Mol Endocrinol 2006; 36: 163-174.
  • 19
    Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004; 45: 1169-1196.
  • 20
    Elovson J, Chatterton JE, Bell GT, Schumaker VN, Reuben MA, Puppione DL, et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res 1988; 29: 1461-1473.
  • 21
    Zambon A, Bertocco S, Vitturi N, Polentarutti V, Vianello D, Crepaldi G. Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins. Biochem Soc Trans 2003; 31: 1070-1074.
  • 22
    Merkel M, Weinstock PH, Chajek-Shaul T, Radner H, Yin B, Breslow JL, et al. Lipoprotein lipase expression exclusively in liver. A mouse model for metabolism in the neonatal period and during cachexia. J Clin Invest 1998; 102: 893-901.
  • 23
    Semenkovich CF, Chen SH, Wims M, Luo CC, Li WH, Chan L. Lipoprotein lipase and hepatic lipase mRNA tissue specific expression, developmental regulation, and evolution. J Lipid Res 1989; 30: 423-431.
  • 24
    Tajmir P, Kwan JJ, Kessas M, Mozammel S, Sweeney G. Acute and chronic leptin treatment mediate contrasting effects on signaling, glucose uptake, and GLUT4 translocation in L6-GLUT4myc myotubes. J Cell Physiol 2003; 197: 122-130.
  • 25
    Stenger C, Hanse M, Pratte D, Mbala ML, Akbar S, Koziel V, et al. Up-regulation of hepatic lipolysis stimulated lipoprotein receptor by leptin: a potential lever for controlling lipid clearance during the postprandial phase. FASEB J 2010; 24: 4218-4228.
  • 26
    Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab 2009; 297: E271-E288.
  • 27
    Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 2005; 54: 795-802.
  • 28
    Seufert J, Kieffer TJ, Habener JF. Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob/ob mice. Proc Natl Acad Sci U S A 1999; 96: 674-679.
  • 29
    Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006; 49: 755-765.
  • 30
    Bamji-Mirza M, Sundaram M, Zhong S, Yao EF, Parks RJ, Yao Z. Secretion of triacylglycerol-poor VLDL particles from McA-RH7777 cells expressing human hepatic lipase. J Lipid Res 2011; 52: 540-548.
  • 31
    Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Aleman JO, Suzuki R, et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 2008; 7: 125-134.
  • 32
    Huang W, Dedousis N, Bandi A, Lopaschuk GD, O'Doherty RM. Liver triglyceride secretion and lipid oxidative metabolism are rapidly altered by leptin in vivo. Endocrinology 2006; 147: 1480-1487.
  • 33
    Lucero D, Zago V, Lopez GH, Cacciagiu L, Lopez GI, Wikinski R, et al. Predominance of large VLDL particles in metabolic syndrome, detected by size exclusion liquid chromatography. Clin Biochem 2012; 45: 293-297.
  • 34
    van der Vleuten GM, Kluijtmans LA, Hijmans A, Blom HJ, Stalenhoef AF, de Graaf J. The Gln223Arg polymorphism in the leptin receptor is associated with familial combined hyperlipidemia. Int J Obes (Lond) 2006; 30: 892-898.
  • 35
    Hoffer MJ, Snieder H, Bredie SJ, Demacker PN, Kastelein JJ, Frants RR, et al. The V73M mutation in the hepatic lipase gene is associated with elevated cholesterol levels in four Dutch pedigrees with familial combined hyperlipidemia. Atherosclerosis 2000; 151: 443-450.
  • 36
    Hoffer MJ, Bredie SJ, Boomsma DI, Reymer PW, Kastelein JJ, de Knijff P, et al. The lipoprotein lipase (Asn291-->Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidaemia. Atherosclerosis 1996; 119: 159-167.